Siglec-2/CD22 Fc Chimera Protein, Human

Siglec-2/CD22 Fc Chimera, Human，2μg，on SDS-PAGE under reducing and Non-reducing condition. The purity is greater than 95%.

2e5 of transient transfected anti-Siglec-2 ScFv CAR-293 cells were stained with 0.1ug Siglec-2/CD22 Fc Chimera Protein, Human, (Cat. No. UA010025) and unlabel respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). Alexa Fluor® 647 signal was used to evaluate the binding activity. 2e5 of transient transfected anti-Siglec-2 ScFv CAR-293 cells were stained with competitor respectively (Fig. D). APC signal was used to evaluate the binding activity. 2e5 of transient transfected anti-Siglec-2 ScFv CAR-293 cells were stained with isotype and Whitlow/218 Linker-Alexa Fluor® 488 (Fig. E and F). Alexa Fluor® 488 signal was used to evaluate the binding activity.

Immobilized Siglec-2/CD22 Fc Chimera, Human (Cat. No. UA010025) at 2.0μg/mL (100μL/well) can bind Biotinylated Anti-Human CD22 (Pinatuzumab)  with EC50 of 4.32-6.15ng/mL.